Here are the 10-K annual reports from Iridex Corp (IRIX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRIX filings page.
IRIDEX Corporation, an ophthalmic medical technology company, reports that total revenues reached $52.7 million in fiscal 2025, up from $48.7 million in 2024, while net loss narrowed to $4.4 million from $8.9 million. The company sells laser consoles and single-use probes for glaucoma and retinal diseases, leveraging its MicroPulse and Endpoint Management technologies. It relies heavily on international sales and a strategic distribution partnership with Topcon, while facing macroeconomic pressures, regulatory complexity and supply-chain risks. IRIDEX also entered into a $4.0 million convertible note with Novel Inspiration International, with the option for up to $10.0 million in additional notes, adding new debt and potential future equity dilution.